Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence.
Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence.
复制标题
DOI：
10.1016/j.tem.2017.04.003
复制
发表时间：
2017-08
期刊：
影响因子：
--
通讯作者：
Deo R
中科院分区：
文献类型：
--
作者：
Leonard CE;Hennessy S;Han X;Siscovick DS;Flory JH;Deo R
磺脲类药物是治疗2型糖尿病最常用的二线药物。虽然磺脲类药物的心血管安全性已在许多试验和非随机研究中得到验证，但对其对心脏骤停和相关严重心律失常的具体影响知之甚少。这种知识差距是惊人的，因为糖尿病患者心脏骤停的风险增加。这篇综述探讨了磺脲类药物对严重心律失常风险的影响，特别关注缺血预处理、心脏兴奋性和严重低血糖的可能机制。阐明单个磺脲类药物与严重心律失常之间的关系至关重要，特别是随着糖尿病流行加剧和糖尿病患者心脏骤停发生率增加。
Sulfonylureas are the most commonly-used second line drug class for treating type 2 diabetes mellitus. While the cardiovascular safety of sulfonylureas has been examined in a number of trials and non-randomized studies, little is known of their specific effects on sudden cardiac arrest and related serious arrhythmic outcomes. This knowledge gap is striking, as persons with diabetes mellitus are at increased risk of sudden cardiac arrest. This review explores sulfonylureas’ influence on the risk of serious arrhythmias, with specific foci on ischemic preconditioning, cardiac excitability, and serious hypoglycemia as putative mechanisms. Elucidating the relationship between individual sulfonylureas and serious arrhythmias is critical, especially as the diabetes epidemic intensifies and sudden cardiac arrest incidence increases in persons with diabetes.
登录
查看更多内容
影响因子：
5.8
作者：
Duan DD
通讯作者：
Duan DD
影响因子：
4.2
作者：
El-Atat, Fadi A;McFarlane, Samy I;Bigger, J Thomas
通讯作者：
Bigger, J Thomas
影响因子：
3.4
作者：
De Ponti, F;Poluzzi, E;Montanaro, N
通讯作者：
Montanaro, N
影响因子：
4.2
作者：
Garcia, Rosa Maria Rahmi;Rezende, Paulo Cury;Hueb, Whady
通讯作者：
Hueb, Whady
影响因子：
20.1
作者：
Hayashi M;Shimizu W;Albert CM
通讯作者：
Albert CM